Summary

Pioneering, proprietary and patented, Two-Dimensional Long-Range Ordering and Clustering, (2D L-ROC) platform, rapid, accurate, label-free COVID-19 antibody testing, COVID-19 antigen testing, structure-based COVID-19 therapeutic, Structure-based COVID-19 vaccine, high-sensitivity functional screening, high-sensitivity molecular imaging, membrane protein, ACE2, SARS-CoV-2, spike (S) glycoprotein, envelope(E)protein, membrane (M) protein, Surface Plasmon Resonance (SPR)

Description

NOVATARG Theranostics proposes sole source small business innovation research (SBIR) projects to deploy its pioneering, proprietary and patented Two-Dimensional Long-Range Ordering and Clustering (2D L-ROC) platform, to enable (1) rapid, accurate, label-free COVID-19 antibody and antigen testing, and (2) structure-based, COVID-19 therapeutic and vaccine interventions. NOVATARG’s advances have the potential to accelerate the U.S. readiness to COVID-19 and other future viral threats for which no effective interventions exist.

Special details

Unique enabling Two-Dimensional Long-Range Ordering and Clustering (2D L-ROC) platform. Integrated with high-sensitivity and high-amplification fluorescence detection of full-length functionally active membrane proteins relevant to their native state. Optimized for integration with Surface Plasmon Resonance for label-free detection. Optimized for novel cryo-electron diffraction for high-resolution characterization of the structure of membrane proteins. Ideally suited for structural and functional screening against ACE2, SARS-CoV-2, spike (S) glycoprotein, envelope(E)protein, membrane (M) protein. Ideally suited for accurate, non-invasive nasopharyngeal, oropharyngeal, and saliva-based COVID-19 testing.

Profile

  • Incorporated in
    Massachusetts
  • Established since
    2015
  • Main/Branch
    Branch

Address